此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.

2013年10月31日 更新者:Boehringer Ingelheim

Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given 200 mg b.i.d. or 400 mg b.i.d. Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.

The main objectives of the multiple dose study are to investigate the safety, tolerability pharmacokinetics of BI 671800 HEA in healthy male and female volunteers following multiple oral administration of BI 671800

研究概览

研究类型

介入性

注册 (实际的)

24

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Ingelheim、德国
        • 1268.59.1 Boehringer Ingelheim Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion criteria:

  1. Healthy males and females according to the following criteria: Based upon a complete medical history, including physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests
  2. Age 21 to 50 years (incl.)
  3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)
  4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria:

  1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  2. Any evidence of a clinically relevant concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. History of relevant orthostatic hypotension, fainting spells or blackouts
  6. Chronic or relevant acute infections
  7. History of relevant allergy or hypersensitivity (including allergy to drug or its excipients)
  8. Intake of drugs with a long half life (>24 h) within one month or less than 10 half-lives of the respective drug prior to first study drug administration
  9. Participation in another trial with an investigational drug within 2 months prior to administration or during the trial
  10. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes daily)
  11. Alcohol abuse (average consumption of more than 20 g/day in females and 30 g/day in males) or positive alcohol test
  12. Drug abuse
  13. Blood donation (more than 100 mL within four weeks prior to day 1 of visit 2)
  14. Any laboratory value outside the reference range that is of clinical relevance, especially repeated Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma-glutamyl-transferase (GGT), Alkaline phosphatase (ALP) or total bilirubin above upper limit of normal (ULN) at screening and not resolved before dosing.
  15. Inability to comply with dietary regimen of trial site
  16. Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval within 10 days prior to administration or during the trial, and CYP2C8 substrates such as amiodarone, amodiaquine, paclitaxel, rosiglitazone, pioglitazone and repaglinide or CYP2C9 such as warfarin, tolbutamide, phenytoin, losartan, acenocoumarol within 1 month or six half lives (whichever is greater).
  17. Repeated demonstration of a QTc interval >450 ms, PR interval >230 ms or a QRS interval >120 ms; history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)

    For female subjects of childbearing potential only:

  18. Positive pregnancy test, pregnancy or planning to become pregnant during the study or within 2 months after study completion
  19. No adequate contraception during the study including three months before first dosing until 2 month after study completion, e.g. not any of the following: implants, injectables, combined hormonal contraceptives, intrauterine device, or surgical sterilisation (including hysterectomy). In addition to this, also a barrier method (e.g. condom) will be required, if the female is not surgically sterilised.
  20. Lactation

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:BI 671800 HEA medium dose
Tablet, oral administration with 240 mL of water for each treatment
High dose oral administration
Medium dose oral administration
实验性的:BI 671800 HEA high dose
2 Tablets, oral administration with 240 mL of water for each treatment
High dose oral administration
Medium dose oral administration
安慰剂比较:Placebo
Matching to HEA 200 mg tablets, oral administration
Matching to HEA 200 mg tablet, oral administration

研究衡量的是什么?

主要结果指标

结果测量
大体时间
不良事件
大体时间:12周
12周
Vital signs (pulse rate (PR))
大体时间:12 weeks
12 weeks
Clinical laboratory test (clinical chemistry)
大体时间:12 weeks
12 weeks
Clinical laboratory test (urinalysis)
大体时间:12 weeks
12 weeks
Physical examination
大体时间:12 weeks
12 weeks
Vital signs (blood pressure (BP))
大体时间:12 weeks
12 weeks
12-lead ECG (electrocardiogram)
大体时间:12 weeks
12 weeks
Clinical laboratory test (haematology)
大体时间:12 weeks
12 weeks
Assessment of tolerability by investigator
大体时间:12 weeks
12 weeks

次要结果测量

结果测量
大体时间
Cmax (maximum plasma concentration of BI 671800 or BI 600957)
大体时间:up to day 12 post treatment
up to day 12 post treatment
tmax (time from dosing until maximum concentration of BI 671800 or BI 600957 is measured)
大体时间:up to day 12 post treatment
up to day 12 post treatment
AUC0-infinity (area under the plasma concentration-time curve of BI 671800 or BI 600957 from time of dosing extrapolated to infinity)
大体时间:up to day 12 post treatment
up to day 12 post treatment
AUCτ,1 (area under the plasma concentration-time curve of BI 671800 or BI 600957 for the complete dosing interval τ)
大体时间:up to day 12 post treatment
up to day 12 post treatment
AUC0-tz (area under the plasma concentration-time curve of BI 671800 or BI 600957 from time of dosing to time tz of last quantifiable concentration)
大体时间:up to day 12 post treatment
up to day 12 post treatment
Cmax,ss (maximum plasma concentration of BI 671800 or BI 600957 at steady state)
大体时间:up to day 12 post treatment
up to day 12 post treatment
tmax,ss (time from dosing until maximum concentration of BI 671800 or BI 600957 at steady state is measured)
大体时间:up to day 12 post treatment
up to day 12 post treatment
Cavg,ss (average measured plasma concentration of BI 671800 or BI 600957 at steady state)
大体时间:up to day 12 post treatment
up to day 12 post treatment
AUCτ,ss (area under the plasma concentration-time curve of BI 671800 or BI 600957 at steady state for the complete dosing interval τ)
大体时间:up to day 12 post treatment
up to day 12 post treatment
λz,ss (terminal rate constant of BI 671800 or BI 600957 in plasma at steady state)
大体时间:up to day 12 post treatment
up to day 12 post treatment
t1/2,ss (terminal half-life of BI 671800 or BI 600957 in plasma at steady state)
大体时间:up to day 12 post treatment
up to day 12 post treatment
MRTpo,ss (mean residence time of BI 671800 in the body at steady state after oral administration)
大体时间:up to day 12 post treatment
up to day 12 post treatment
CL/F,ss (apparent clearance of BI 671800 at steady state following oral administration)
大体时间:up to day 12 post treatment
up to day 12 post treatment
Vz/F,ss (apparent volume of distribution of BI 671800 during the terminal phase at steady state following oral administration)
大体时间:up to day 12 post treatment
up to day 12 post treatment
RAUCτ,ss,M/P (ratio of AUCτ,ss of the BI 600957 to AUCτ,ss of BI 671800)
大体时间:up to day 12 post treatment
up to day 12 post treatment
RCmax,ss,M/P (ratio of Cmax,ss of the BI 600957 to Cmax,ss of BI 671800)
大体时间:up to day 12 post treatment
up to day 12 post treatment
accumulation ratios RA,Cmax
大体时间:up to day 12 post treatment
up to day 12 post treatment
accumulation ratios RA,AUC
大体时间:up to day 12 post treatment
up to day 12 post treatment
peak-trough fluctuation (PTF) of BI 671800
大体时间:up to day 12 post treatment
up to day 12 post treatment
peak-trough fluctuation (PTF) of BI 600957
大体时间:up to day 12 post treatment
up to day 12 post treatment
linearity index (LI) of BI 671800 in plasma
大体时间:up to day 12 post treatment
up to day 12 post treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2010年10月1日

初级完成 (实际的)

2010年12月1日

研究注册日期

首次提交

2010年9月29日

首先提交符合 QC 标准的

2010年10月6日

首次发布 (估计)

2010年10月7日

研究记录更新

最后更新发布 (估计)

2013年11月1日

上次提交的符合 QC 标准的更新

2013年10月31日

最后验证

2013年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • 1268.59
  • 2009-016369-27 (EudraCT编号:EudraCT)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅